Semax / Selank

Scientific identity — Semax component: Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, derived from the ACTH(4–7) core sequence with a C-terminal Pro-Gly-Pro extension for metabolic stability. Its ACTH(4–7) tetrapeptide core — Met-Glu-His-Phe — corresponds to the shared pharmacophore region of ACTH and α-MSH and has been investigated in melanocortin receptor pharmacology and BDNF-related CNS signalling research.

Scientific identity — Selank component: Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with the same C-terminal Pro-Gly-Pro stability extension. Tuftsin is a naturally occurring tetrapeptide fragment of the Fc region of IgG, studied in immunomodulatory and neuropeptide signaling research. Selank has been investigated in GABAergic signalling models, enkephalin degradation research, and CNS anxiolytic biology in experimental systems.

Research areas: Neuropeptide pharmacology, BDNF pathway research, GABAergic signalling models, melanocortin-related CNS research, tuftsin analogue biology, POMC-derived peptide research, combined neuropeptide research tools.

Product format: Single vial containing both peptides combined.

Purity: Each peptide component characterised to greater than 99% individual purity, confirmed by HPLC and LC-MS analysis at the batch level.

Analytical documentation: A batch-specific Certificate of Analysis is available on the Longevia Research website, covering identity, purity, and lot traceability for both peptide components.

Research-use classification: For laboratory research use only. Not for human or veterinary use, clinical diagnostics, or any in-vivo application in humans.

Semax: ACTH(4–7) Core Sequence and BDNF Research

Semax preserves the Met-Glu-His-Phe tetrapeptide pharmacophore shared by ACTH and α-MSH — both POMC-derived peptides with melanocortin receptor activity. Research has examined Semax in animal models investigating BDNF mRNA and protein expression in brain regions, with findings suggesting BDNF pathway engagement following Semax administration in rodent CNS tissue. The molecular mechanism connecting ACTH(4–7) sequence engagement to BDNF expression changes is an active research question characterised in defined preclinical systems. Research has also examined Semax in CNS ischemia models and oxidative stress systems in neural cells.

Selank: Tuftsin Analogue and GABAergic Research

Selank is derived from tuftsin — a naturally occurring Fc-derived tetrapeptide with established immunomodulatory properties. As a synthetic heptapeptide analogue, Selank has been investigated in GABAergic signaling research, with animal studies examining interactions with GABA-A receptor-related pathways in CNS models. Research has also examined Selank in relation to enkephalin-degrading enzyme activity, proposing a mechanism involving reduced enkephalin degradation as a contributing factor to observed anxiolytic-related behavioral endpoints in rodent paradigms. These are experimental research hypotheses characterised in defined animal systems.

Shared Pro-Gly-Pro Stability Architecture

The C-terminal Pro-Gly-Pro extension present in both Semax and Selank is a shared synthetic stability element that reduces susceptibility to carboxypeptidase degradation, extending the functional half-life of each peptide in biological systems relative to their respective parent sequences. This shared structural feature makes the Semax/Selank combination of interest in comparative neuropeptide stability research examining the consequences of identical C-terminal modification on peptides with distinct N-terminal pharmacophores.

Combination Research Context

The Semax/Selank blend is supplied as a combined research preparation for investigators examining the two neuropeptides in parallel experimental systems. Each peptide retains its individual molecular identity and pharmacological characteristics within the blend. Research findings from each peptide's independent literature should not be assumed to apply to the combined preparation without experimental verification; combined-peptide interactions in biological systems are a separate research question not established in the current literature.

Pharmaceutical Development Context

Both Semax and Selank have been subjects of pharmaceutical development and clinical investigation in Russia, where each has been investigated under specific regulatory frameworks. Neither holds FDA nor EMA approval for any indication. Published clinical findings concern pharmaceutical-grade individual formulations under Russian regulatory conditions and do not establish the safety, efficacy, or bioavailability of the Longevia Research combined research vial.

Reliable research begins with accurately characterised material. For a combination vial containing two distinct synthetic heptapeptides, that means confirming the sequence integrity, purity, and identity of each component individually at the batch level — because co-formulation of two peptides requires verification that each is present at its stated quantity and that neither component contains sequence errors or truncations that would confound experiments designed around either peptide's specific pharmacological profile.

Purity assessment: Each peptide component in this blend is characterised to greater than 99% individual purity by high-performance liquid chromatography (HPLC). Chromatographic purity data for both components is reported on the batch Certificate of Analysis.

Identity confirmation: The identity of both Semax and Selank is confirmed by mass spectrometry (LC-MS), providing molecular-weight verification consistent with the complete heptapeptide sequence of each component. HPLC and LC-MS data together confirm that both materials supplied correspond to their labelled compounds at the labelled purities.

Batch traceability and Certificate of Analysis: Every vial of the Semax/Selank Blend 10mg/10mg is traceable to a specific production lot. A batch-specific Certificate of Analysis is accessible directly on the Longevia Research website, covering purity, identity, and lot information for both components. Researchers evaluating this material are encouraged to review the current batch documentation before use.

Handling: This material should be handled by qualified personnel using appropriate laboratory technique and personal protective equipment, consistent with institutional protocols for research-grade synthetic neuropeptides.

Longevia Research supplies the Semax/Selank Blend 10mg/10mg for laboratory and in-vitro research use only. The product is intended for use by qualified researchers and trained laboratory personnel in appropriate controlled research environments.

Both Semax and Selank are synthetic research peptides supplied strictly as research tools. This combination vial is not a drug, not a dietary supplement, not a food or food ingredient, and not a cosmetic. Neither Semax nor Selank holds FDA or EMA approval for any therapeutic indication. References to their pharmaceutical use in Russian clinical contexts concern regulated individual formulations under specific regulatory frameworks that do not apply to this Longevia Research combined research vial, which is not a pharmaceutical product and has not been evaluated by any regulatory authority for safety or efficacy in this formulation.

Longevia provides no dosing instructions, administration guidance, treatment protocols, or reconstitution recommendations for this combination product. The scientific literature summarised on this product page describes experimental observations from individual peptide research in defined cell-based, animal, and limited clinical systems. Those findings are not medical claims and should not be interpreted as evidence of human efficacy, human safety, or fitness for any clinical application from this product.

The purchaser assumes full responsibility for lawful acquisition, handling, storage, use, and disposal of this material, and for compliance with all applicable local, state, federal, and institutional regulations. By purchasing this product, the buyer confirms that it will be used solely for legitimate laboratory research purposes by qualified personnel, and that its acquisition and intended use comply with applicable laws in the buyer's jurisdiction.